AngioDynamics Inc. Common Stock (ANGO)
Stock · NASDAQ · Health Care
$11.24as of 10/16/2026
Price chart
ANGO Signal Track Record
How signals performed across all stocks →What ANGO's price did in the 20 trading sessions after each past signal, compared with any 20-session window over the same period.
| Signal | Times | Median 20-session return | Higher after 20 sessions | Last signal |
|---|---|---|---|---|
| Volume Spike | 38 | -6.0% | 42% | October 2, 2026 |
| Bollinger Band Breakout | 23 | +0.2% | 57% | July 15, 2026 |
| Bollinger Band Breakdown | 21 | -2.3% | 48% | October 6, 2026 |
| 200-Day Moving Average TouchActive now | 17 | 0.0% | 47% | June 3, 2026 |
| Any 20-session window (baseline) | -0.1% | 49% |
Computed by MarketWall from daily closing prices since May 18, 2022. Returns are close-to-close and don't include dividends. Past results describe what happened before; they are not a forecast and not investment advice.
About ANGO
AngioDynamics, Inc., a medical technology company, designs, manufactures, and sells products for the treatment of cardiovascular disease and cancer diagnoses in the United States and internationally. The company operates through Med Tech and Med Device segments. It offers Auryon Atherectomy system that delivers an optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium. T…
- Sector
- Health Care
- Industry
- Medical/Dental Instruments
- Employees
- 632
- Website
- www.angiodynamics.com/
Fundamentals
- 1-day range
- $11.31$11.71
- Market cap
- $624.53M
- P/E (trailing)
- —
- P/E (forward)
- -253.33
- EPS (trailing)
- $-0.89
- Dividend yield
- —
- Beta
- 0.20
- Avg. volume
- 598.4K
How AngioDynamics Inc. Common Stock Makes Money
Where the revenue actually goes — FY2026 annual results
Source: 10-K filed Jul 14, 2026 · via SEC EDGAR / Finnhub
Forecasts
4 analyst ratings
AngioDynamics Inc. Common Stock Competitors
Chosen by industry and closest market cap.
- ANGOAngioDynamics Inc. Common Stock$11.24▼ 2.94%Market cap $624.53MP/E —$9.39$16.29
- BWAYBrainsWay Ltd. American Depositary Shares$11.44▼ 3.21%Market cap $626.52MP/E 53.55$2,391$5,123
- BBNXBeta Bionics Inc. Common Stock$16.35▼ 5.55%Market cap $634.80MP/E —$8.8$32.71
- MDXGMiMedx Group Inc Common Stock$4.43▼ 5.34%Market cap $609.28MP/E 109.34$3.03$7.97
- TCMDTactile Systems Technology Inc. Common Stock$22.52▼ 3.31%Market cap $650.97MP/E 21.02$14.43$37.77
- KIDSOrthoPediatrics Corp. Common Stock$21.95▼ 2.75%Market cap $549.03MP/E —$14.42$26.74
- DCTHDelcath Systems Inc. Common Stock$14.08▼ 4.93%Market cap $534.05MP/E 962.21$8.12$17.42
| Symbol | Market cap | P/E ratio | Price | 1D | 52-week range |
|---|---|---|---|---|---|
| ANGO AngioDynamics Inc. Common Stock | $624.53M | — | $11.24 | ▼ 2.94% | $9.39$16.29 |
| BWAY BrainsWay Ltd. American Depositary Shares | $626.52M | 53.55 | $11.44 | ▼ 3.21% | $2,391$5,123 |
| BBNX Beta Bionics Inc. Common Stock | $634.80M | — | $16.35 | ▼ 5.55% | $8.8$32.71 |
| MDXG MiMedx Group Inc Common Stock | $609.28M | 109.34 | $4.43 | ▼ 5.34% | $3.03$7.97 |
| TCMD Tactile Systems Technology Inc. Common Stock | $650.97M | 21.02 | $22.52 | ▼ 3.31% | $14.43$37.77 |
| KIDS OrthoPediatrics Corp. Common Stock | $549.03M | — | $21.95 | ▼ 2.75% | $14.42$26.74 |
| DCTH Delcath Systems Inc. Common Stock | $534.05M | 962.21 | $14.08 | ▼ 4.93% | $8.12$17.42 |
P/E shows — for peers not currently carrying a live signal of their own.
Latest news
- ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/YYahoo · 10/9/2026
- AngioDynamics (ANGO) Q1 2027 Earnings Call TranscriptYahoo · 10/9/2026
- AngioDynamics, Inc. Q1 2027 Earnings Call SummaryYahoo · 10/8/2026
- Why AngioDynamics Crashed TodayYahoo · 10/8/2026
- Traders are paying attention to the gapping stocks in Thursday's session.ChartMill · 10/8/2026
- AngioDynamics Q1 Earnings Call HighlightsYahoo · 10/8/2026
- AngioDynamics, Inc. 2027 Q1 - Results - Earnings Call PresentationSeekingAlpha · 10/8/2026
- AngioDynamics Stock Is Falling Thursday: What's Going On?Benzinga · 10/8/2026
Insider Activity
Insider Actions →- Nighan Warren JR · July 30, 2026 · Sale23.4K @ $14.72
- Piccinini Laura · July 22, 2026 · Option Exercise28.3K
- Piccinini Laura · July 22, 2026 · Tax Withholding4.5K @ $13.82
- Piccinini Laura · July 22, 2026 · Option Exercise8.0K
- Nighan Warren JR · July 22, 2026 · Option Exercise20.1K
- Nighan Warren JR · July 22, 2026 · Tax Withholding1.7K @ $13.82
- Nighan Warren JR · July 22, 2026 · Option Exercise5.7K
- Trowbridge Stephen A · July 22, 2026 · Option Exercise57.4K
- Trowbridge Stephen A · July 22, 2026 · Tax Withholding8.3K @ $13.82
- Trowbridge Stephen A · July 22, 2026 · Option Exercise16.3K
- Clemmer James C · July 22, 2026 · Option Exercise184.4K
- Clemmer James C · July 22, 2026 · Tax Withholding26.7K @ $13.82
- Clemmer James C · July 22, 2026 · Option Exercise52.4K
- Campbell Chad Thomas · July 22, 2026 · Option Exercise22.8K
- Campbell Chad Thomas · July 22, 2026 · Tax Withholding2.3K @ $13.82
Institutional Ownership
March 31, 2026
- Total shares held
- 37.86M
- Total value held
- $422.94M
- Institutional holders
- 141
- Unknown3.69M
- Unknown3.18M
- Unknown2.45M
- Unknown2.07M
- Unknown1.87M
- Unknown1.73M
- Unknown1.53M
- Unknown1.37M
- Unknown1.33M
- Unknown1.31M
See the full, filterable feed with live charts on the MarketWall dashboard.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 29, 2026
ANGO Announces Q1 Fiscal 2027 Results Date
AngioDynamics (ANGO) will report its fiscal 2027 first‑quarter earnings on Oct. 8, 2026. The earnings release will provide updated guidance on revenue, operating income and cash flow for the quarter. Analysts will review the results to assess the company’s performance against expectations. The announcement is the main event for the stock this week.
ANGO Announces Q1 Fiscal 2027 Results Date. AngioDynamics (ANGO) will report its fiscal 2027 first‑quarter earnings on Oct. 8, 2026. The earnings release will provide updated guidance on revenue, operating income and cash flow for the quarter. Analysts will review the results to assess the company’s performance against expectations. The announcement is the main event for the stock this week.